Finance

Lists
Why is 4142 down 3.26%?
Dive Deeper
4142:TPE
Adimmune Corp
NT$17.80
-3.26%
(-0.60) 1D
Oct 19, 1:30:05 PM GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 4142...
Open
NT$18.40
High
NT$18.40
Low
NT$17.80
Mkt. cap
7.65B
Avg. vol.
1.04M
Volume
1.30M
52-wk high
NT$22.50
52-wk low
NT$16.40
EPS
-NT$0.34
Shares outstanding
235.29M
No. of employees
564
Open
NT$18.40
High
NT$18.40
Low
NT$17.80
Mkt. cap
7.65B
Avg. vol.
1.04M
Volume
1.30M
52-wk high
NT$22.50
52-wk low
NT$16.40
EPS
-NT$0.34
Shares outstanding
235.29M
No. of employees
564
News stories
From web sources and news partners
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets. Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026. Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations. In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease. In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022. In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorBiotechnology
Previous reportsAll values in TWD
Loading Previous Earnings...
Revenue
Net income
All values in TWD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
475.32M
745.46M
82.32M
66.76M
Cost of goods sold
390.92M
376.00M
156.87M
129.59M
Cost of revenue
390.92M
376.00M
156.87M
129.59M
Research and development expenses
38.46M
74.68M
45.44M
30.55M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
95.91M
94.80M
79.22M
79.34M
Operating expense
146.27M
197.18M
124.66M
109.88M
Total operating expenses
537.18M
573.18M
281.54M
239.47M
Operating income
-61.86M
172.28M
-199.22M
-172.71M
Other non operating income
249.00K
10.40M
710.00K
2.18M
EBT including unusual items
-38.56M
200.77M
-200.47M
-172.95M
EBT excluding unusual items
-38.56M
200.30M
-198.95M
-172.95M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18.26M
220.42M
-185.54M
-160.23M
Net profit margin
-3.84%
29.57%
-225.41%
-240.02%
Earnings per share
-
-
-
-
Interest and investment income
2.85M
9.92M
3.10M
6.47M
Interest expense
-8.82M
-10.40M
-7.40M
-6.95M
Net interest expenses
-5.97M
-475.00K
-4.30M
-480.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.68M
219.90M
-156.74M
-128.36M
Gain or loss from assets sale
-
-3.00K
-
-
AI content may include mistakes. Learn more
Google apps